Thaum Lub Ib Hlis 13, 2026, Tuam Tshoj Biopharmaceuticals (1177. HK) tshaj tawm tias nws yuav tau txais tag nrho Hangzhou Hejiya Biopharmaceutical Co., Ltd. (tom qab no hu ua "Hejiya"), lub tuam txhab tshuaj tshiab hauv kev lag luam me me cuam tshuam nucleic acid (siRNA) tag nrho cov nqi ntawm Tuam Tshoj. Los ntawm qhov kev tau txais no, Tuam Tshoj Biopharmaceutical tau txais ib qho kev ywj pheej technology platform, muaj ntau yam khoom pipelines, thiab cov kws R & D pab neeg nyob rau hauv lub siRNA teb, ntxiv enriching pab pawg neeg cov pipeline layout nyob rau hauv lub teb ntawm cov kab mob.
1. General Specification (hauv Tshuag)
(1) API (Ntshiab hmoov)
(2) Cov ntsiav tshuaj
(3) Capsules
(4) Txau
(5) Pill press machine
https://www.achievechem.com/pill-xwm
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
PIB: BM-2-4-009
Tirzepatide CAS 2023788-19-2
Lub khw tseem ceeb: Tebchaws Asmeskas, Australia, Brazil, Nyiv, Lub Tebchaws Yelemees, Indonesia, UK, New Zealand, Canada thiab lwm yam.
Chaw tsim tshuaj paus: BLOOM TECH Xi'an Hoobkas
Peb muabtirzepatide hmoov, thov xa mus rau lub vev xaib hauv qab no kom paub meej specifications thiab cov ntaub ntawv khoom.
Khoom siv:https://www.bloomtechz.com/news/peptides-nqi- npe- ntawm-bloom-tech-85355837.html
Hegia tau tsim muaj nyob rau hauv 2018 thiab yog ib lub tuam txhab pioneering biopharmaceutical tsom rau kev tshawb fawb thiab kev loj hlob ntawm sRNA cov tshuaj tshiab. Pab pawg R & D coj los ntawm Cui Kunyuan muaj ntau dua 20 xyoo ntawm kev paub dhau los hauv kev txhim kho cov tshuaj nucleic acid me me, tau txais ntau tshaj 50 cov ntaub ntawv tseem ceeb, thiab tau tsim kom muaj kev sib koom ua ke ntawm kev tsim tshuaj tshiab los ntawm lub hom phiaj tshawb pom mus rau kev soj ntsuam lub tswv yim pov thawj (POC). Nrog 6 lub siab loj / cov khoom xa tawm sab nraud, Hejiya kev xa khoom zoo thiab cov khoom lag luam muaj peev xwm ua tau zoo ua ntej ntawm qib kev lag luam, thiab nws tau suav tias yog "tus nees tsaus" hauv thaj chaw me me nucleic acid.
MVIP lub siab lub hom phiaj platform: lub ntiaj teb thawj zaug thiab tam sim no tib lub chaw kho mob tau lees paub sIRNA kev xa khoom thev naus laus zis platform uas tuaj yeem ua tiav "ib koob tshuaj ib xyoos" ntev - ua yeeb yam xa tawm. Hauv ob qho tib si hauv vitro thiab hauv vivo cov qauv, nws tau qhia kev xa khoom zoo tshaj plaws thiab kev ua tau zoo piv rau cov platform zoo sib xws. Nws yog thawj siRNA kev xa khoom thev naus laus zis platform hauv Suav teb kom tau txais kev tso cai patent thoob ntiaj teb, thiab nws cov kev ua haujlwm siab, kev nyab xeeb, thiab kev ua haujlwm ntev - tau raug sim nyob rau hauv ntau lub kav dej pov thawj.
DDP dual target delivery platform: It can synchronously deliver dual target siRNA, achieving a synergistic therapeutic effect of "1+1>2 ". Nyob rau hauv lub neej yav tom ntej, los ntawm combining sib txawv cov ntaub so ntswg lub hom phiaj platforms, nws muaj peev xwm tsim rau complex los yog refractory kab mob kho los ntawm ntau lub hom phiaj thiab mechanisms, uas muaj ib tug tseem ceeb technologies cuam tshuam lub peev xwm.
NSDP Neural Targeting Platform: Cov txheej txheem yav tom ntej rau kev xa khoom hauv thaj chaw ntawm cov kab mob hauv lub paj hlwb, ua tiav cov kev xav tau kho tsis tau zoo ntawm CNS (central nervous system) thiab PNS (peripheral nervous system). Pib txij xyoo 2026, cov khoom lag luam yuav nkag mus rau theem kho mob, pab nthuav cov raj xa mus rau ntau qhov chaw muaj kab mob.
Thawj tus neeg mob hauv Phase I kev sim tshuaj kom ua tiav tau txais kev kho siRNA rau ALS kho nrog Ruikang los ntawm Tuam Tshoj thiab Tebchaws Meskas
Thaum Lub Ib Hlis 13, 2026, Zhongmei Ruikang tau tshaj tawm tias nws tus kheej tau tsim kho tshiab siRNA kho RAG-17 tsom rau S0D1 mutant amyotrophic lateral sclerosis (ALS, feem ntau hu ua "Zhezong syndrome") tau ua tiav thawj tus neeg mob kev tswj hwm hauv theem I kev sim tshuaj nyob rau hauv Tsev Kho Mob Thib Ob Affiliated Tsev Kawm Ntawv ntawm Zheji. Qhov kev sim no tau coj los ntawm xibfwb Wu Zhiying, Tus Thawj Coj ntawm Lub Tsev Haujlwm Saib Xyuas Kev Kho Mob caj ces / Tsis tshua muaj kab mob kuaj thiab kho qhov chaw kho mob hauv tsev kho mob.
Qhov kev sim tshuaj multicenter no yog ib qho randomized, ob npaug - qhov muag tsis pom, placebo- tswj kev kawm nrog ntau qhov koob tshuaj nce ntxiv (MAD) tsom rau kev ntsuas kev nyab xeeb / kam rau ua, PK, PD, thiab kev ua tau zoo ua ntej ntawm kev txhaj tshuaj intrathecal ntawm RAG-17 hauv ALS gene mutations. Cov koom haum koom nrog hauv qhov kev sim no suav nrog Beijing Tuam Tsev Kho Mob Saum Ntuj Ceeb Tsheej koom nrog Capital Medical University (Xib Fwb Wang Yilong pab pawg), Lub Tsev Kho Mob Thib Ob ntawm Zhejiang University School of Medicine (Xib Fwb Wu Zhiying pab pawg),
West China Tsev Kho Mob ntawm Sichuan University (Xib Fwb Shang Huifang pab neeg), Union Medical College Tsev Kho Mob koom nrog Fujian Medical University (Xib Fwb Zou Tanyu pab pawg), thiab Thawj Koom Haum Tsev Kho Mob ntawm Sun Yat sen University (Xib Fwb Zeng Jinsheng pab pawg)
RAG-17 yog ib qho tshiab siRNA tshuaj ntawm nws tus kheej tsim los ntawm Zhongmei Ruikang, tso siab rau lub tuam txhab cov tswv cuab SCADm (Tshwj xeeb tshuaj pab xa khoom) kev xa khoom platform thev naus laus zis.
Cov tshuaj no yog tsom rau tshwj xeeb thiab ua tau zoo lub hom phiaj thiab ntsiag to mRNA qhia ntawm SOD1 noob rau kev kho mob ntawm ALS nqa SOD1 noob hloov. Kev tau txais cov tshuaj lom neeg ua haujlwm los ntawm kev hloov pauv hauv 5OD1 noob yog ib qho tseem ceeb ntawm cov kab mob hauv tsev neeg ALS. Los ntawm kev ua haujlwm zoo inhibiting SOD1 noob qhia thiab txo qis kev tsim cov tshuaj lom SOD1 protein, RAG-17 lub hom phiaj los tiv thaiv kev ua haujlwm neuronal, yog li ncua lossis tiv thaiv kab mob kev loj hlob ntawm SOD1-ALS.